ETF Series Solutions - Loncar China BioPharma ETF (Nasdaq:CHNA) - Stock Price, News & Analysis

CHNA Stock Overview

ETF Series Solutions - Loncar China BioPharma ETF is an exchange traded fund launched by ETF Series Solutions.

CHNA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

ETF Series Solutions - Loncar China BioPharma ETF Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ETF Series Solutions - Loncar China BioPharma ETF
Historical stock prices
Current Share Price	US$13.53
52 Week High	US$22.89
52 Week Low	US$13.53
Beta	0
1 Month Change	-6.66%
3 Month Change	-17.50%
1 Year Change	-4.01%
3 Year Change	-54.92%
5 Year Change	-29.79%
Change since IPO	-43.15%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CHNA	US Capital Markets	US Market
7D	-5.0%	7.3%	3.3%
1Y	-4.0%	19.3%	20.9%

Return vs Industry: CHNA underperformed the US Capital Markets industry which returned 8% over the past year.

Return vs Market: CHNA underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is CHNA's price volatile compared to industry and market?
CHNA volatility
CHNA Average Weekly Movement	4.5%
Capital Markets Industry Average Movement	2.2%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.0%

Stable Share Price: CHNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CHNA's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	n/a	https://loncarfunds.com/chna

ETF Series Solutions - Loncar China BioPharma ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC. The fund invests in public equity markets of China.

ETF Series Solutions - Loncar China BioPharma ETF Fundamentals Summary

How do ETF Series Solutions - Loncar China BioPharma ETF's earnings and revenue compare to its market cap?
CHNA fundamental statistics
Market Cap	US$3.72m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is CHNA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CHNA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CHNA perform over the long term?

See historical performance and comparison